Weiss Ratings Reiterates "Hold (C+)" Rating for Lifevantage (NASDAQ:LFVN)

Key Points

• Weiss Ratings has maintained a "Hold (C+)" rating for Lifevantage (NASDAQ:LFVN) after issuing a report on Wednesday.
• Lifevantage's stock was previously downgraded by Wall Street Zen from a "buy" rating to a "hold" rating on October 3rd, indicating a shift in analyst sentiment.
• Lifevantage's recent quarterly earnings showed a net margin of 4.29% and a return on equity of 33.75%, with reported EPS matching analysts' expectations at $0.17.

Lifevantage (NASDAQ:LFVN - Get Free Report)'s stock had its "hold (c+)" rating reissued by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded shares of Lifevantage from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Lifevantage currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.50.

Lifevantage Trading Down 0.5%

NASDAQ:LFVN opened at $9.20 on Wednesday. The firm has a 50-day moving average price of $11.91 and a two-hundred day moving average price of $12.69. Lifevantage has a twelve month low of $9.11 and a twelve month high of $27.38. The company has a market capitalization of $116.75 million, a P/E ratio of 12.43 and a beta of 0.26.

Lifevantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings results on Thursday, September 4th. The company reported $0.17 EPS for the quarter, hitting analysts' consensus estimates of $0.17. The business had revenue of $55.11 million during the quarter, compared to the consensus estimate of $57.93 million. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. During the same period in the previous year, the firm posted $0.14 earnings per share. Lifevantage has set its FY 2026 guidance at 1.000-1.15 EPS.

Insider Buying and Selling

In related news, Director Michael A. Beindorff sold 4,125 shares of the firm's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $11.44, for a total value of $47,190.00. Following the completion of the transaction, the director directly owned 22,858 shares of the company's stock, valued at $261,495.52. This trade represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.95% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lifevantage

A number of hedge funds have recently made changes to their positions in the company. Ritholtz Wealth Management increased its position in Lifevantage by 27.8% in the first quarter. Ritholtz Wealth Management now owns 60,510 shares of the company's stock worth $882,000 after purchasing an additional 13,162 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Lifevantage by 23.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company's stock valued at $188,000 after purchasing an additional 2,421 shares in the last quarter. Cannon Global Investment Management LLC bought a new stake in Lifevantage in the 1st quarter valued at approximately $156,000. Calamos Advisors LLC bought a new stake in Lifevantage in the 1st quarter valued at approximately $490,000. Finally, Brown Advisory Inc. bought a new stake in Lifevantage in the 1st quarter valued at approximately $150,000. Institutional investors and hedge funds own 35.32% of the company's stock.

Lifevantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.